More potential for sildenafil than potency

Circulation

Volumn 112, Issue 19, 2005, Pages 2894-2895

  Mahler, Felix ^a   Baumgartner, Iris ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Editorials; Pharmacology; Raynaud's phenomenon

Indexed keywords

SILDENAFIL;

CARDIOVASCULAR DISEASE; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; EDITORIAL; HEADACHE; HUMAN; MUCOSA INFLAMMATION; NAUSEA; PRIORITY JOURNAL; RAYNAUD PHENOMENON; SIDE EFFECT; SYMPATHECTOMY; VISUAL DISORDER;

HUMANS; MALE; PENILE ERECTION; PIPERAZINES; RAYNAUD DISEASE; VASODILATOR AGENTS;

EID: 27744450610     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.577643     Document Type: Editorial

References (14)

1. Roth Philip. The Human Stain. Boston, Mass: Houghton Mifflin: 2000.
2. Fries R, Shariat K, von Wilmowsky H, Böhm M. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation. 2005;112:2980-2985.
3. Baumhaekel M, Scheffler P, Boehm M. Use of tadalafil in a patient with a secondary Raynaud's phenomenon not responding to sildenafil. Microvasc Res. 2005;69:178-179.
4. Heslop J, Coggon D. The prevalence of intermittent digital ischemia (Raynaud's phenomenon) in a general practice. J Roy Coll Gen Pract. 1983;33:85-89.
5. Wigley FM. Raynaud's phenomenon. N Engl J Med. 2002;347:1001-1008.
6. Webb DJ, Muirhead GJ, Wulff M, Sutto JA, Levi R, Dinsmore WW. Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. J Am Coll Cardiol. 2000;36:25-31.
7. Halcox JP, Nour KR, Zalos G, Mincemoyer RA, Waclawiw M, Rivera CE, Willie G, Ellahham S, Quyyumi AA. The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol. 2002;40:1232-1240.
8. Rosenkranz S, Diet F, Karasch T, Weihrauch J, Wassermann K, Erdmann E. Sildenafil improved pulmonary hypertension and peripheral blood flow in patient with scleroderma-associated lung fibrosis and the Raynaud phenomenon. Ann Intern Med. 2003;139:871-873.
9. Aldashev AA, Kojonazarov BK, Amatov TA, Sooronbaev TM, Mirrakhimov MM, Morrell NW, Wharton J, Wilkins MR. Phosphodiesterase type 5 and high altitude pulmonary hypertension. Thorax. 2005;60:683-687.
10. Park JW, Mrowietz C, Chung N, Jung F. Sildenafil improves cutaneous microcirculation in patients with coronary artery disease: a monocentric prospective, double-blind, placebo-controlled, randomized cross-over study. Clin Hemorheol Microcirc. 2004;31:173-183.
11. Lichtenstein JR. Use of sildenafil citrate in Raynaud's phenomenon: comment on the article by Thompson et al. Arthritis Rheum. 2003;48:282-283. Letter.
12. Kamata Y, Kamimura T, Iwamoto M, Minota S. Comparable effects of sildenafil citrate and alprostadil on severe Raynaud's phenomenon in a patient with systemic sclerosis. Clin Exp Dermatol. 2005;30:451.
13. Schoeffel DA, Kiekenbeck A, Dinges H. Sildenafil in the treatment of scleroderma: proceedings of the Annual European Congress of Rheumatology. Ann Rheum Dis. 2003;62(suppl 2):AB #03235.
14. Gore J, Silver R. Oral sildenafil for the treatment of Raynaud phenomenon and digital ulcers secondary to systemic sclerosis. Ann Rheum Dis. 2005;64:1387.